Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
CMTA-STAR Clinical Expert Board Co-Chair Prof. Mary Reilly Honored with Prestigious MBE
…clinical care for people with CMT worldwide. Beyond her research and clinical work, Prof. Reilly has led the development of key institutions dedicated to advancing neuromuscular disease research. She co-founded…
CMTA-STAR Awards $1.1 Million for CMT1X, CMT2A Clinical Trials
Latest research grants bring CMTA-STAR total to $17 million GLENOLDEN, PENNSYLVANIA, USA, March 23, 2021 — The Charcot-Marie-Tooth Association | Strategy to Accelerate Research (CMTA-STAR) announced $1.1 million in grants…
Inherited Neuropathies Consortium Study 6611: Charcot-Marie-Tooth disease Infant Scale
…Role in Advancing Research As the global leader in driving transformative progress in CMT research, CMTA, through its alliance with INC, is committed to advancing patient-centered research that delivers meaningful…
NMD Pharma Receives FDA Approval to Initiate Phase II Clinical Trial of NMD670 in CMT Patients
…the ongoing research will lead to significant advancements in treating CMT and improving the lives of those affected by this condition. Register with Patients as Partners in Research Today CMTA…
The CMTA Appoints Professor Charlotte Sumner, M.D., to its Scientific Advisory Board
Professor Charlotte Sumner, M.D., CMTA Strategy to Accelerate Research (STAR) Scientific Advisory Board The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research that’s aimed at bringing…
Funding
…not be accepted After the CMTA Board of Directors acts, the CMTA will document, agree and sign off on the research plan with the research investigator institution. Evaluation Approach Project…
Keep Hope Alive for Everyone Living with CMT
…CMTA has invested over $17 million in CMTA-STAR research since 2008, making us the largest chartable funder of CMT research globally. But our work isn’t done: Our strategy outlines investments…